Why eXoZymes Is Standing Out to Investor James Tissot
James Tissot, founder and author of Slack Capital, an independent research publication focused on uncovering asymmetric investment opportunities through high-conviction analysis, sees the emergence of eXoZymes (NASDAQ: EXOZ) as a different kind of biotech story.
International Business Times ·